Michelle E. Melisko, MD
Although chemotherapy may have a lesser role in breast cancer treatment for select patients, there are still high-risk populations who will derive benefit from this modality, said Michelle E. Melisko, MD.
State of the Science Summit™ on Breast Cancer, Melisko, a clinical professor of medicine at the University of California, San Francisco, discussed the clinical implications of the TAILORx and MINDACT studies.
OncLive: Please provide an overview of your presentation at the State of the Science Summit.TM
: I reviewed the clinical trials that have recently been published and presented, including MINDACT for MammaPrint and the TAILORx trial, which looked at the value of the Oncotype DX assay to predict the benefit of chemotherapy in patients with HR-positive, HER2-negative breast cancer. I gave a brief historical reference of how we used to give chemotherapy to almost all patients with estrogen receptor (ER)-positive, HER2-negative breast cancers.
... to read the full story